Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. (Q48770670)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

plaque psoriasis

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Alexandra Boer Kimball

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Andrew Blauvelt

3

object named as

Andrew Blauvelt

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1

object named as

Kristian Reich

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

6

object named as

Diamant Thaçi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Stephen K Tyring

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Rodney Sinclair

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Kristine Nograles

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Anish Mehta

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Nicole Cichanowitz

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Qing Li

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Kenneth Liu

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Carmen La Rosa

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Stuart Green

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

language of work or name

0 references

publication date

6 June 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

390

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

10091

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

276-288

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Psoriasis--epidemiology and clinical spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of keratinocyte protein kinase C zeta in psoriasis plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The psychosocial burden of psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-23: a key cytokine in inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutting edge: A critical functional role for IL-23 in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical improvement in psoriasis with specific targeting of interleukin-23.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Secukinumab in plaque psoriasis--results of two phase 3 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Th17 cells in immunity to Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of secukinumab in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of cardiovascular risk factors in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931279-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)31279-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596043%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48770670&oldid=1858814652"